glp-1 agonist access guide
Stop Trusting Mainstream Obesity Treatment Insurance Access
Stop Trusting Mainstream Obesity Treatment Insurance Access Insurance coverage for prescription weight loss is fundamentally flawed because benefit designs treat obesity as a non-chronic condition, leading to systematic denials even when clinical criteria are met. Patients often meet FDA indications for semaglutide or tirzepatide, yet a cascade of prior-authorization obstacles